Skip to Content

The Potential of Trodelvy® for Patients with HR+/HER2- Metastatic Breast Cancer Patients Treated with Trodelvy®

Sacituzumab Govitecan Is a First-in-Class Trop-2‒Directed Antibody-Drug Conjugate. In this MEDtalk Professor of Medicine Hope S. Rugo, MD, University of California San Francisco, gives her perspective of Sacituzumab Govitecan for patients with HR+/HER2- Metastatic Breast Cancer.

Hope Rugo

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top